English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/53143
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:


Insights into the molecular inactivation mechanism of human activated thrombin-activatable fibrinolysis inhibitor

AuthorsSanglas, Laura; Arolas, Joan L. ; Valnickova, Zuzana; Avilés, Francesc X.; Enghild, Jan J.; Gomis-Rüth, F. Xavier
Issue Date2010
CitationJournal of Thrombosis and Haemostasis 8: 1056-1065 (2010)
AbstractBackground: Thrombin-activatable fibrinolysis inhibitor (TAFI) is a validated target for thrombotic diseases. TAFI is converted in vivo to activated TAFI (TAFIa) by removal of its pro-domain. Whereas TAFI is stable and persists in the circulation, possibly in complex with plasminogen, TAFIa is unstable and poorly soluble, with a half-life of minutes.Objectives: In order to study the molecular determinants of this instability, we studied the influence of protein inhibitors on human TAFIa. Results: We found that protein inhibitors significantly reduced the instability and insolubility of TAFIa. In addition, we solved the 2.5-Å resolution crystal structure of human TAFIa in complex with a potent protein inhibitor, tick-derived carboxypeptidase inhibitor, which gives rise to a stable and soluble TAFIa species. The structure revealed a significant reduction in the flexibility of dynamic segments when compared with the structures of bovine and human TAFI. We also identified two latent hotspots, loop Lβ2β3 and segment α5-Lα5β7-β7, where conformational destabilization may begin. These hotspots are also present in TAFI, but the pro-domain may provide sufficient stabilization and solubility to guarantee protein persistence in vivo. When the pro-domain is removed, the free TAFIa moiety becomes unstable, its activity is suppressed, and the molecule becomes insoluble. Conclusions: The present study corroborates the function of protein inhibitors in stabilizing human TAFIa and it provides a rigid and high-resolution mold for the design of small molecule inhibitors of this enzyme, thus paving the way for novel therapy for thrombotic disorders. © 2010 International Society on Thrombosis and Haemostasis.
Identifiersdoi: 10.1111/j.1538-7836.2010.03740.x
issn: 1538-7933
e-issn: 1538-7836
Appears in Collections:(IBMB) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
Show full item record
Review this work

Related articles:

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.